Nasdaq:VOR

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

November 08, 2025 11:45 ET  | Source: Vor Biopharma Treatment with telitacicept for 39 weeks resulted in a rapid, clinically…

4 weeks ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease

October 22, 2025 16:30 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

1 month ago

Vor Bio to Participate in the Stifel2025 Virtual Immunology and Inflammation Forum

September 12, 2025 16:15 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

3 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 16:35 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

4 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:00 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

5 months ago